文献速递核素与放射性配体治疗肿瘤 PET/CT

单一螯合剂-微型双抗体诊疗剂用于89Zr PET显像和177Lu放射药物治疗PSMA表达的前列腺癌

Single Chelator-Minibody Theranostic Agents for 89Zr PET Imaging and 177Lu Radiopharmaceutical Therapy of PSMA-Expressing Prostate Cancer.
PubMed 文献 · J Nucl Med · 2024-09-03

本研究将抗PSMA微型双抗体IAB2MA偶联八齿大环螯合剂L804,并用89Zr标记用于PET显像、177Lu标记用于放射药物治疗,在PC3-PIP荷瘤小鼠中与DOTA和DFO螯合剂比较。L804可在室温下30分钟内实现>99%放射化学产率标记;177Lu-L804-IAB2MA在肿瘤和所有检查器官中的摄取显著低于177Lu-DOTA-IAB2MA,且吸收剂量更低、毒性更小;单次18.4或22.2 MBq的177Lu-L804-IAB2MA较未标记微型双抗体对照显著延长生存并缩小肿瘤体积,但与177Lu-DOTA-IAB2MA组生存无显著差异。作者认为89Zr-和177Lu-L804-IAB2MA可能是前列腺癌显像与治疗的有前景的诊疗对。

要点

  • L804-IAB2MA与177Lu或89Zr在室温下30分钟内标记,放射化学产率>99%。
  • 177Lu-L804-IAB2MA在肿瘤及所有检查器官的摄取显著低于177Lu-DOTA-IAB2MA。
  • 单次177Lu-L804-IAB2MA(18.4或22.2 MBq)较未标记对照显著延长生存、缩小肿瘤体积。

核心结论

  • 作者认为89Zr-和177Lu-L804-IAB2MA可能是有前景的诊疗对,用于前列腺癌的显像与治疗。

研究设计与样本

  • 在PSMA阳性PC3-PIP荷瘤小鼠前列腺癌模型中,将L804与现行金标准螯合剂DOTA和DFO偶联于IAB2MA,进行177Lu和89Zr标记、细胞结合、临床前生物分布、显像、剂量学和疗效研究。

主要发现

  • L804-IAB2MA与177Lu或89Zr在室温下30分钟内实现>99%放射化学产率,与89Zr标记DFO-IAB2MA相当;而DOTA-IAB2MA与177Lu在37°C标记30分钟放射化学产率约90%,需进一步纯化。
  • 以铕(III)作为发光替代物,Eu-L804-IAB2MA对PC3-PIP细胞PSMA的解离常数为4.6±0.6 nM。
  • 4种放射性标记构建物在PC3-PIP细胞中30分钟后的内化水平均显著高于PSMA阴性PC3-FLU细胞。
  • 注射后96小时(177Lu)和72小时(89Zr),177Lu-和89Zr-L804-IAB2MA在PC3-PIP肿瘤及所有检查器官(心、肝、脾、肾、肌肉、唾液腺、泪腺、残骸和骨)的摄取显著低于177Lu-DOTA-IAB2MA和89Zr-DFO-IAB2MA。
  • SPECT/CT和PET/CT显像数据一般显示各放射性示踪剂在肿瘤或肌肉的SUVmean无显著差异。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Here we describe an anti-prostate-specific membrane antigen (PSMA) minibody (IAB2MA) conjugated to an octadentate, macrocyclic chelator based on four 1-hydroxypyridin-2-one coordinating units (Lumi804 [L804]) labeled with 89Zr (PET imaging) and 177Lu (radiopharmaceutical therapy), with the goal of developing safer and more efficacious treatment options for prostate cancer. Methods: L804 was compared with the current gold standard chelators, DOTA and deferoxamine (DFO), conjugated to IAB2MA for radiolabeling with 177Lu and 89Zr in cell binding, preclinical biodistribution, imaging, dosimetry, and efficacy studies in the PSMA-positive PC3-PIP tumor-bearing mouse model of prostate cancer. Results: Quantitative radiolabeling (>99% radiochemical yield) of L804-IAB2MA with 177Lu or 89Zr was achieved at ambient temperature in under 30 min, comparable to 89Zr labeling of DFO-IAB2MA. In contrast, DOTA-IAB2MA was radiolabeled with 177Lu for 30 min at 37°C in approximately 90% radiochemical yield, requiring further purification. Using europium(III) as a luminescent surrogate, high binding affinity of Eu-L804-IAB2MA to PSMA was demonstrated in PC3-PIP cells (dissociation constant, 4.6 ± 0.6 nM). All 4 radiolabeled constructs showed significantly higher levels of internalization after 30 min in the PC3-PIP cells than in PSMA-negative PC3-FLU cells. The accumulation of 177Lu- and 89Zr-L804-IAB2MA in PC3-PIP tumors and all organs examined (i.e., heart, liver, spleen, kidney, muscle, salivary glands, lacrimal glands, carcass, and bone) was significantly lower than that of 177Lu-DOTA-IAB2MA and 89Zr-DFO-IAB2MA at 96 and 72 h after injection, respectively. Generally, SPECT/CT and PET/CT imaging data showed no significant difference in the SUVmean of the tumors or muscle between the radiotracers. Dosimetry analysis via both organ-level and voxel-level dose calculation methods indicated significantly higher absorbed doses of 177Lu-DOTA-IAB2MA in tumors, kidney, liver, muscle, and spleen than of 177Lu-L804-IAB2MA. PC3-PIP tumor-bearing mice treated with single doses of 177Lu-L804-IAB2MA (18.4 or 22.2 MBq) exhibited significantly prolonged survival and reduced tumor volume compared with unlabeled minibody control. No significant difference in survival was observed between groups of mice treated with 177Lu-L804-IAB2MA or 177Lu-DOTA-IAB2MA (18.4 or 22.2 MBq). Treatment with 177Lu-L804-IAB2MA resulted in lower absorbed doses in tumors and less toxicity than that of 177Lu-DOTA-IAB2MA. Conclusion: 89Zr- and 177Lu-L804-IAB2MA may be a promising theranostic pair for imaging and therapy of prostate cancer.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Ho KV, Tatum DS, Watkinson L, et al. Single Chelator-Minibody Theranostic Agents for 89Zr PET Imaging and 177Lu Radiopharmaceutical Therapy of PSMA-Expressing Prostate Cancer. J Nucl Med. 2024. PMID: 39142831. doi:10.2967/jnumed.124.267667

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。